Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab

Summary

The rationale of the ROSY-D study is to continue to provide study treatment for patients who have participated in a parent study with Durvalumab and who are continuing to derive clinical benefit from treatment at the end of such studies, as judged by the Investigator.

Timeline

Start

2022-04-19

Primary completion

2026-12-31

Completion

2026-12-31

Drugs

Indications